Showing papers in "Blood Advances in 2021"
Fred Hutchinson Cancer Research Center1, University of Washington2, Ottawa Hospital Research Institute3, Medical University of Vienna4, University of Chieti-Pescara5, University of Toronto6, Case Western Reserve University7, University of California, San Francisco8, Provincial Health Services Authority9, University of British Columbia10, McMaster University11, Cardiff University12, University of Minnesota13, American University of Beirut14, Cochrane Collaboration15
TL;DR: In this paper, the authors present evidence-based guidelines of the American Society of Hematology (ASH) to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer.
284 citations
University of Pennsylvania1, University of Toronto2, McMaster University3, Cochrane Collaboration4, Mahidol University5, Johns Hopkins University6, Albert Einstein College of Medicine7, NewYork–Presbyterian Hospital8, Columbia University9, McGill University10, Leiden University Medical Center11, Yale University12, Pontifical Catholic University of Chile13, Kaiser Permanente14, University of Geneva15, Washington University in St. Louis16, Ottawa Hospital Research Institute17, American University of Beirut18, St. Joseph's Healthcare Hamilton19, University of Guadalajara20, King Hussein Cancer Center21, University of Chicago22, University of Freiburg23
TL;DR: The evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected venous thromboembolism (VTE) as mentioned in this paper.
263 citations
TL;DR: In this paper, the authors carried out proteomic profiling of plasma from cross-sectional and longitudinal cohorts of hospitalized patients with COVID-19 and analyzed clinical data from a health system database of more than 3300 patients.
200 citations
Queen's University1, Brigham and Women's Hospital2, Princeton University3, Rutgers University4, Washington University in St. Louis5, Leiden University Medical Center6, University of Washington7, Auckland City Hospital8, Launceston General Hospital9, Royal College of Surgeons in Ireland10, Emory University11, Medical College of Wisconsin12, University of Kansas13
TL;DR: In this article, the authors present evidence-based guidelines of the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemopathilia (WFH) for von Willebrand disease (VWD) diagnosis.
177 citations
Brigham and Women's Hospital1, Medical College of Wisconsin2, McMaster University3, University College London4, Marquette University5, University of Rochester6, Imperial College London7, Royal College of Surgeons in Ireland8, Erasmus University Medical Center9, Ohio State University10, State University of Campinas11, University of Michigan12, Queen's University13, University of Kansas14
TL;DR: In this article, the authors present evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemopathilia (WFH) intended to support patients, clinicians, and health care professionals in their decisions about management of VWD.
122 citations
TL;DR: In this paper, the humoral immune response to BNT162b2 mRNA COVID-19 vaccine was evaluated in patients with B-NHL who received two vaccine doses 21 days apart and compared with the response in healthy controls.
114 citations
TL;DR: This article is the first to describe the dissemination of extreme levels of EV-TF in patients with severe COVID-19, which supports the international recommendations of systematic preventive anticoagulation in hospitalized patients and potential intensification of anticoAGulation in Patients with severe disease.
82 citations
73 citations
TL;DR: In this paper, the authors reported clinical hematologic manifestations and unique bone marrow (BM) features in 16 patients with VEXAS, all of whom were male and had a history of severe autoinflammatory and rheumatologic manifestations.
70 citations
TL;DR: Azacitidine + venetoclax, decitabine+ venetocaine, and low-dose cytarabine + Venetocax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML).
68 citations
TL;DR: In this paper, the authors evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) at a single center.
TL;DR: The RBD of SARS-CoV-2 shares sequence similarity with an ancient lectin family known to bind blood group antigens as mentioned in this paper, which can be used to directly link blood group A and SARS CoV2.
TL;DR: The authors performed a systematic review of the literature on vaccine responsiveness in patients who have received anti-CD20 therapy, including patients with hematologic malignancy or autoimmune disease, using a random-effects model.
TL;DR: In this paper, the authors retrospectively identified 6 patients with VEXAS who underwent allogeneic hematopoietic stem cell transplantation (ASCT), and four patients were guided by life-threatening autoinflammatory symptoms that were refractory to multiple therapies.
TL;DR: In this article, the authors examined immune reconstitution in 60 patients receiving bone marrow or peripheral blood stem cell (PBSC) grafts after haplo-HCT with PTCy and 35 patients receiving HLA-matched donor PBSC grafts with standard graft-versus-host disease (GVHD) prophylaxis.
University of Pennsylvania1, University of Toronto2, McMaster University3, Mahidol University4, Johns Hopkins University5, Albert Einstein College of Medicine6, NewYork–Presbyterian Hospital7, Columbia University8, McGill University9, Leiden University Medical Center10, Yale University11, Pontifical Catholic University of Chile12, Kaiser Permanente13, University of Geneva14, Washington University in St. Louis15, Ottawa Hospital Research Institute16, University of Oklahoma Health Sciences Center17, American University of Beirut18, St. Joseph's Healthcare Hamilton19, University of Guadalajara20, King Hussein Cancer Center21, University of Chicago22, University of Freiburg23, University of Kansas24
TL;DR: In 2019, the American Society of Hematology (ASH) developed guidelines to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected venous thromboembolism (VTE) as discussed by the authors.
TL;DR: In this article, the authors retrospectively analyzed the efficacy and safety of CPX-351 in a real-world setting in 103 patients from 12 French centers, including the evaluation of molecular abnormalities at baseline and minimal residual disease (MRD) in responding patients, compared with a historical data set from Bordeaux-Toulouse DATAML registry.
TL;DR: In this paper, the authors leveraged electronic health record data from a multisite research network to identify Black patients with COVID-19 who have SCD/SCT and those who do not have SCT.
TL;DR: In this paper, a subset of patients with primary CNS lymphoma (PCNSL; n=5) were treated with CD19CAR T cells in an ongoing Phase 1 clinical trial (NCT02153580).
TL;DR: In this paper, the antibody-drug conjugate polatuzumab vedotin (pola) was used as a bridging treatment for patients with refractory or relapsed large B-cell lymphoma.
TL;DR: In this article, the effect of SARS-CoV-2 vaccination on preexisting complementopathies is investigated, and the authors describe the recrudescence of 2 autoimmune conditions (ITP and acquired von Willebrand Disease [AvWD]/acquired hemophilia A) and 1 complementopathy (paroxysmal nocturnal hemoglobinuria [PNH]).
TL;DR: Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies as mentioned in this paper.
TL;DR: The upregulation of podoplanin (PDPN) by cancer cells has been linked to an increased risk for venous thromboembolism (VTE) in GBM patients as discussed by the authors.
TL;DR: In this paper, a novel strategy to treat β-thalassemias based on genome editing of the α-globin locus in human hematopoietic stem/progenitor cells (HSPCs) was described.
TL;DR: In this article, the authors established the SECURE-SCD registry to identify factors associated with hospitalization and serious COVID-19 illness in children and adults with SCD, and they used multivariable logistic models to estimate the independent effects of age, sex, genotype, hydroxyurea, and SCD-related and non-related comorbidities on hospitalization, serious acute respiratory syndrome coronavirus 2 infection.
TL;DR: In this paper, the authors evaluated the association between EASIX and other laboratory parameters collected before lymphodepletion and the subsequent onset of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) those patients.
TL;DR: In this article, the authors evaluated the humoral response by determining the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with Waldenstrom macroglobulinemia (WM) after vaccination with the BNT162b2 or AZD1222 vaccine.
TL;DR: A cross-talk between NETs and inflammasomes both in vitro and in the DVT setting is demonstrated, suggesting that this may be an important mechanism supporting thrombosis in veins.